Cargando…

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review

INTRODUCTION: Radio-ligand targeted therapy is a new and promising concept of treatment Castration resistant prostate cancer (CRPC). Only a few radio-pharmaceutics were approved for usage in treating prostate cancer, among the multiple others tested. We aimed to review and summarize the literature o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szponar, Paweł, Petrasz, Piotr, Brzeźniakiewicz-Janus, Katarzyna, Drewa, Tomasz, Zorga, Piotr, Adamowicz, Jan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687416/ https://www.ncbi.nlm.nih.gov/pubmed/38033494 http://dx.doi.org/10.3389/fonc.2023.1239118

Ejemplares similares

Tissue engineering in reconstructive urology—The current status and critical insights to set future directions-critical review
por: Ławkowska, Karolina, et al.
Publicado: (2023)

Tissue Engineering and Its Potential to Reduce Prostate Cancer Treatment Sequelae—Narrative Review
por: Adamowicz, Jan, et al.
Publicado: (2021)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Quinolones as a Potential Drug in Genitourinary Cancer Treatment—A Literature Review
por: Kloskowski, Tomasz, et al.
Publicado: (2022)

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status
por: Lütje, Susanne, et al.
Publicado: (2015)

PSMA PET in Imaging Prostate Cancer
por: Tsechelidis, Ioannis, et al.
Publicado: (2022)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

PSMA-targeted therapy for non-prostate cancers
por: Wang, Jarey H., et al.
Publicado: (2023)

Modern urology perspectives on prostate cancer biomarkers
por: Szeliski, Kamil, et al.
Publicado: (2018)

Tumor Cell-Induced Platelet Aggregation as an Emerging Therapeutic Target for Cancer Therapy
por: Strasenburg, Wiktoria, et al.
Publicado: (2022)

Is there a link between soft drinks and erectile dysfunction?
por: Adamowicz, Jan, et al.
Publicado: (2011)

Focal therapy of prostate cancer: Assessment with prostate-specific membrane antigen (PSMA) imaging
por: Topoozian, Mark, et al.
Publicado: (2023)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

A Review of 177Lutetium-PSMA and 225Actinium-PSMA as Emerging Theranostic Agents in Prostate Cancer
por: Alam, Mohammad R, et al.
Publicado: (2022)

Tissue engineering of urinary bladder – current state of art and future perspectives
por: Adamowicz, Jan, et al.
Publicado: (2013)

Editorial: Exploring the Potential of PSMA-PET Imaging on Personalized Prostate Cancer Treatment
por: Ilhan, Harun, et al.
Publicado: (2022)

Efficacy of PSMA PET-Guided Radiotherapy for Oligometastatic Castrate-Resistant Prostate Cancer
por: Henkenberens, Christoph, et al.
Publicado: (2021)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
por: Arbuznikova, Daria, et al.
Publicado: (2023)

α–blockade, apoptosis, and prostate shrinkage: how are they related?
por: Chłosta, Piotr, et al.
Publicado: (2013)

Current thromboprophylaxis in urological cancer patients during COVID-19 pandemic
por: Ostrowski, Adam, et al.
Publicado: (2022)

Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review
por: Shah, Hina J., et al.
Publicado: (2023)

May patients receiving 5-alpha-reductase inhibitors be in higher risk of COVID-19 complications?
por: Adamowicz, Jan, et al.
Publicado: (2020)

RAS: Striking at the Core of the Oncogenic Circuitry
por: Gimple, Ryan C., et al.
Publicado: (2019)

Targeted Prostate Biopsy Using (68)Gallium PSMA-PET/CT for Image Guidance
por: Simopoulos, Demetrios N., et al.
Publicado: (2017)

Incorporating PSMA-Targeting Theranostics Into Personalized Prostate Cancer Treatment: a Multidisciplinary Perspective
por: Ng, Thomas S. C., et al.
Publicado: (2021)

Role of PSMA PET-guided metastases-directed therapy in oligometastatic recurrent prostate cancer
por: Alberto, Matthew, et al.
Publicado: (2022)

Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review
por: Yan, Li, et al.
Publicado: (2023)

En-bloc resection of urinary bladder tumour – a prospective controlled multicentre observational study
por: Poletajew, Sławomir, et al.
Publicado: (2020)

Predictive and prognostic potential of pretreatment (68)Ga-PSMA PET tumor heterogeneity index in patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA
por: Assadi, Majid, et al.
Publicado: (2022)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

PSMA-targeted [(18)F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
por: Reyes, Diane K., et al.
Publicado: (2019)

The View Outside of the Box: Reporting Outcomes Following Radical Cystectomy Using Pentafecta From a Multicenter Retrospective Analysis
por: Zapała, Łukasz, et al.
Publicado: (2022)

Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis
por: Hupe, Marie Christine, et al.
Publicado: (2018)

(68)Ga-PSMA-11 PET/CT versus (68)Ga-PSMA-11 PET/MRI for the detection of biochemically recurrent prostate cancer: a systematic review and meta-analysis
por: Huang, Ruizhe, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [(177)Lu]Lu-PSMA therapy in relapsing high-grade glioma
por: Truckenmueller, Peter, et al.
Publicado: (2022)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
por: Pan, Ke-Hao, et al.
Publicado: (2021)

Isolated, PSMA-negative penile metastasis from castration resistant prostate adenocarcinoma, identified by FDG-PET
por: Chau, Matthew, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bnsdvd8hub7g4sdtkgt49fbf3j